Giovanna Marrapese

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Digital workload in oncology trials: A comparative analysis of e-portal usage and operational insights from a single-center experience.

Digital workload in oncology trials: A comparative analysis of e-portal usage and operational insights from a single-center experience.

Journal: Tumori

Published: February 03, 2026

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies.

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies.

Journal: Drugs

Published: September 08, 2025

Management of Increasing Complexity of Phase I Trials: A Retrospective Analysis from the Niguarda Cancer Center Phase I Unit.

Management of Increasing Complexity of Phase I Trials: A Retrospective Analysis from the Niguarda Cancer Center Phase I Unit.

Journal: Therapeutic innovation & regulatory science

Published: January 30, 2025

Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers.

Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers.

Journal: Journal of clinical pathology

Published: December 09, 2023

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report.

Journal: JTO clinical and research reports

Published: May 22, 2023

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.

Journal: Expert review of anticancer therapy

Published: April 01, 2020

Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.

Journal: Clinical colorectal cancer

Published: March 20, 2020

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

Journal: The oncologist

Published: November 15, 2018

TRKA expression and NTRK1 gene copy number across solid tumours.

TRKA expression and NTRK1 gene copy number across solid tumours.

Journal: Journal of clinical pathology

Published: February 26, 2018

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Journal: Targeted oncology

Published: July 03, 2017

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Journal: Cancer discovery

Published: November 03, 2016

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Journal: The Lancet. Oncology

Published: January 13, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026